Givosiran Sodium

CHEMBL4594265 Phase 4 Aprovado Oligonucleotide

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

This is the sodium salt form of givosiran, an RNAi-based therapy for acute hepatic porphyria. It reduces the production of the enzyme ALAS1 in the liver, lowering toxic aminolevulinic acid (ALA) and porphobilinogen (PBG) levels that cause porphyria attacks. The salt formulation is used in the approved injectable product.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

This is the sodium salt form of givosiran, an RNAi-based therapy for acute hepatic porphyria. It reduces the production of the enzyme ALAS1 in the liver, lowering toxic aminolevulinic acid (ALA) and porphobilinogen (PBG) levels that cause porphyria attacks. The salt formulation is used in the approved injectable product.

Yes, Givosiran Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Oligonucleotide.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4594265. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Procura informações acessíveis para o paciente?

Givosiran Sodium no PillFYI

Dados Rápidos

Sinônimos: 1

Links Externos

ChEMBL CHEMBL4594265

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.